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Androgen receptors are present in 30-50% ofprimary breast
carcinomas (Bretani et al., 1986; Miller et al., 1985; Bryan et
al., 1984) and their presence is correlated with oestrogen
receptor positivity (Bretani et al., 1986; Miller et al., 1985),
age in post-menopausal women (Bretani et al., 1986) and
response to endocrine therapy, but not to chemotherapy
(Bryan et al., 1984). The administration of pharmacologic
doses of androgen (fluoxymestrone) has shown anti-tumour
activity in women refractory to tamoxifen (Manni et al.,
1981) but is associated with virilising side effects. Since both
high doses of oestrogens as well as anti-oestrogens such as
tamoxifen are clinically active in post-menopausal patients
with breast cancer, an anti-androgen might be expected to
have similar therapeutic efficacy to androgens, but without
virilising side effects. Anandron (RU-23908) (5,5-dimethyl-
3(4-nitro-3(trifluoromethyl)phenyl)2, 4 imidazolidinedione) is
a nonsteroidal anti-androgen that competitively inhibits the
effects of testosterone at the receptor level (Moguilewsky et
al., 1987). It is considered to be a pure anti-androgen since it
has no androgenic, oestrogenic, anti-oestrogenic, progesto-
mimetic or antiprogesterone activity and does not bind to the
mineralocorticoid or glucocorticoid receptor. After oral ad-
ministration it is rapidly and completely absorbed with a
slow plasma half-life allowing once daily dosage when steady
state levels are achieved after 2 weeks (Moguilewsky et al.,
1987). Anandron in doses of 100-300 mg day-' has been
used in men with metastatic prostate cancer either after or in
combination with medical or surgical castration and has been
well tolerated (Moguilewsky et al., 1987; Kuhn et al., 1989).
Here we report a phase II clinical study using Anandron in
post-menopausal women with advanced breast cancer and
the resulting endocrine effects. As far as we are aware this is
the first use of Anandron in breast cancer.
Postmenopausal (including post therapeutic oophorec-
tomy) women with measurable advanced breast cancer pro-
gressing on standard therapy and a life expectancy of 3
months were eligible for entry on study. Anandron was given
in a dose of 100 mg once daily continuously. Patients were
assessed clinically at weekly intervals for the first 4 weeks
then 4 weekly until disease progression. Hormone assays
were performed for oestradiol, follicle stimulating hormone
(FSH), luteinising hormone (LH) and sex hormone binding
globulin (SHBG) in ten patients and 5-alpha dihydrotes-
tosterone (DHT) in four patients using previously described
methods (Ferguson et al., 1982; Dowsett et al., 1985; Dow-
sett et al., 1987; Dowsett et al., 1989).
Fifteen patients were enrolled on study. One patient who
did not attend for any follow up visits and was of indeter-
minate menopausal status was excluded from analysis. The
remaining patients are all evaluable for response and toxicity.
Patient details are shown in Table I. Three patients had had
Table I Patient details
No. ofpatients
Age mean (year)
range
Previous endocrine therapy
tamoxifen
aminoglutethimide
progestogen
oophorectomy
LHRH agonist
ketoconazole
Response to previous endocrine therapy
yes
no
not assessable
Disease sites
local recurrence
lymph node
cutaneous
lung
bone
pleura
contralateral primary
liver
Dominant disease site
loco-regional
visceral
bone
14
70
46-87
14 pts
12 pts
7 pts
3 pts
2 pts
2 pts
7 pts
5 pts
2 pts
7 pts
2 pts
4 pts
6 pts
6 pts
2 pts
I pt
I pt
9 pts
4 pts
1 Pt
a previous therapeutic oophorectomy. The median number of
previous endocrine therapies was three (range one to four)
and ten patients had previously received chemotherapy, prin-
cipally single agent mitoxantrone, for advanced disease. Oes-
trogen receptor status of the primary tumour was known for
only two patients both of whom were positive. The lack of
oestrogen receptor measurements is attributable to the use of
non-surgical methods of treatment for primary disease .in
most patients because of its advanced nature or the patients'
advanced age.
No objective responses were seen. Two patients had
disease stabilisation; one for 26 weeks (lung-previous res-
ponse to tamoxifen, but progression on aminoglutethimide/
hydrocortisone and megestrol acetate) and one for 20 weeks
(breast, bone, lung-previous progression on tamoxifen). The
latter patient has had stable disease on aminoglutethimide/
hydrocortisone for 42+ weeks followving progression on
Anandron. The other patient with stable disease did not
receive further therapy. Of the 11 patients who had progres-
sive disease on Anandron four had subsequent alternative
hormone therapy with one brief partial response to megestrol
acetate and five had subsequent chemotherapy with no objec-
tive responses.
There was no toxicity definitely related to Anandron. One
patient stopped treatment after 4 weeks because of subjective
swelling and altered sensation on one side of the tongue and
suspicion of an allergic reaction but was found to have
progression of bone metastases in the base of the skull.
Another patient died at home following a chest infection
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while taking Anandron, but an autopsy was not performed
and therefore the syndrome of Anandron-related interstitial
pneumonitis which has been reported in 2% of patients
treated with Anandron could not be excluded. Anandron has
been reported to induce difficulty with visual light/dark adap-
tation in 24% of men treated for prostatic carcinoma
(Moguilewsky et al., 1987) but despite specific questioning no
patient in this study reported this side-effect.
The results of the endocrine measurements are shown in
Table II. No significant changes were seen although there
was a rise in SHBG that approached significance (P = 0.09).
This study did not demonstrate any objective responses
using Anandron, however two patients had stabilisation of
previously progressive disease for > 20 weeks. Howell et al.
(Howell et al., 1988) have shown that this duration of disease
stability with endocrine therapy for advanced breast cancer
confers the same progression free and overall survival advan-
tage as partial response and therefore Anandron may have
some anti-tumour activity in advanced breast cancer. Al-
though our patients were mainly elderly with loco-regional
disease they had received a median of three previous endo-
crine therapies and the majority previous chemotherapy and
it is possible that more definite anti-tumour activity would be
seen in less heavily pre-treated patients. A National Cancer
Institute of Canada Clinical Trials Group study (Perrault et
al., 1988) using a closely similar anti-androgen (flutamide)
found one partial response and five stable disease in 29
evaluable women with advanced breast cancer, but premeno-
pausal and known oestrogen receptor negative patients were
TableII Effect ofAnandron onmean( ± s.e.m.) oestradiol, FSH, LH,
5-alpha DHT and SHBG in postmenopausal women
P value
Baseline Week 4 (2 tail)
Estradiol (pmol 1') 64.4 ± 24.9 59.0 ± 19.0 0.55
FSH (IU I1) 29.2 ± 6.8 26.2 ± 7.1 0.22
LH (IU 1-) 25.3 ± 6.4 26.4 ± 7.0 0.61
5-alpha DHT (nmol 1-') 0.16 ± 0.02 0.14 ± 0.02 0.59
SHBG (nmol l-') 53.1 ± 11.1 72.4 13.6 0.09
included. Unlike Anandron, flutamide was associated with
troublesome gastro-intestinal toxicity.
There were no significant changes in the endocrine para-
meters suggesting that Anandron has no major peripheral
endocrine effects in postmenopausal women. There was a
tendency for elevation of SHBG which is consistent with the
known action of exogenous androgens in suppressing plasma
levels of SHBG. The lack of a major measurable endocrine
effect does not however exclude a pharmacologic effect
through interaction with tumour androgen receptors. Higher
doses of Anandron have been used in men with prostatic
cancer (Moguilewsky et al., 1987) and it is possible that a
different dose may have different effects in post-menopausal
women. Further clinical and endocrine evaluation of Anan-
dron is justified in minimally pre-treated, potentially
hormone sensitive breast cancer given its low incidence of
toxicity. Where possible patient's tumour tissue should be
assayed for androgen receptor content.
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